Patent Owner's Current List of Exhibits | Aug 4, 2025 | PAPER | PATENT OWNER |
Exhibit 2001 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2002 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2003 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2004 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2005 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2006 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2007 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2008 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2009 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2010 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2011 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2012 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2013 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2014 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2015 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2016 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2017 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2018 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2019 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2020 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2021 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2022 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2023 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2024 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2025 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2026 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2027 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2028 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2029 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2030 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2031 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2032 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2033 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2034 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Exhibit 2035 | Aug 4, 2025 | EXHIBIT | PATENT OWNER |
Patent Owner's Brief Requesting Discretionary Denial of Institution | Aug 4, 2025 | PAPER | PATENT OWNER |
Notice: Notice filing date accorded | Jun 4, 2025 | PAPER | BOARD |
Power of Attorney for Patent Owner Helsinn Healthcare S.A. | May 22, 2025 | PAPER | PATENT OWNER |
Patent Owner's Mandatory Notices | May 22, 2025 | PAPER | PATENT OWNER |
U.S. Patent 8,623,826 B2, issued 17 January 2014 | May 1, 2025 | EXHIBIT | PETITIONER |
U.S. Patent 9,186,357 B2, issued 17 November 2015 | May 1, 2025 | EXHIBIT | PETITIONER |
U.S. Patent 9,943,515 B2, issued 17 April 2018 | May 1, 2025 | EXHIBIT | PETITIONER |
U.S. Patent 10,828,297 B2, issued 10 November 2020 | May 1, 2025 | EXHIBIT | PETITIONER |
Prosecution history for U.S. Appl. 13/077,462, filed 31 March 2011, Pt1 | May 1, 2025 | EXHIBIT | PETITIONER |
Prosecution history for U.S. Appl. 13/077,462, filed 31 March 2011, Pt2 | May 1, 2025 | EXHIBIT | PETITIONER |
Prosecution history for U.S. Appl. 14/069,927, filed 01 November 2013 | May 1, 2025 | EXHIBIT | PETITIONER |
Prosecution history for U.S. Appl. 15/003,327, filed 19 May 2016, Pt1 | May 1, 2025 | EXHIBIT | PETITIONER |
Prosecution history for U.S. Appl. 15/003,327, filed 19 May 2016, Pt2 | May 1, 2025 | EXHIBIT | PETITIONER |
Prosecution history for U.S. Appl. 15/923,050, filed 16 March 2018 | May 1, 2025 | EXHIBIT | PETITIONER |
J. Herrstedt & P. Dombernowsky, Anti-Emetic Therapy in Cancer Chemotherapy | May 1, 2025 | EXHIBIT | PETITIONER |
T. Hoffmann et al., Design and synthesis of a novel | May 1, 2025 | EXHIBIT | PETITIONER |
R. Hargreaves, Imaging Substance P Receptors (NK1) | May 1, 2025 | EXHIBIT | PETITIONER |
The Antiemetic Subcommittee of the Multinational Association of Supportive | May 1, 2025 | EXHIBIT | PETITIONER |
M. Bös et al., 4-phenyl-pyridine derivatives, U.S. Patent 6,297,375 | May 1, 2025 | EXHIBIT | PETITIONER |
Eisai, Inc., ALOXI (palonosetron HCl) Capsules, package insert (Aug. 2008) | May 1, 2025 | EXHIBIT | PETITIONER |
J.D. Herrington et al., Randomized, Placebo-controlled | May 1, 2025 | EXHIBIT | PETITIONER |
D. Bonadeo et al., Soft Capsules Comprising Palonosetron Hydrochloride | May 1, 2025 | EXHIBIT | PETITIONER |
R.J. Gralla et al., Recommendations for the use of antiemetics | May 1, 2025 | EXHIBIT | PETITIONER |
K. Jordan et al., Guidelines for Antiemetic Treatment of Chemotherapy | May 1, 2025 | EXHIBIT | PETITIONER |
Curriculum Vitae of Dr. Stephen J. Peroutka | May 1, 2025 | EXHIBIT | PETITIONER |
G.K. Reddy et al., Novel Neurokinin-1 Antagonists as Antiemetics | May 1, 2025 | EXHIBIT | PETITIONER |
M.S. Aapro et al., A phase III, double-blind, randomized trial | May 1, 2025 | EXHIBIT | PETITIONER |
D. Campos et al., Prevention of cisplatin-induced emesis | May 1, 2025 | EXHIBIT | PETITIONER |
A.E. Chang et al., eds., Oncology: An Evidence-Based Approach (2006) | May 1, 2025 | EXHIBIT | PETITIONER |
S.P. Chawla et al., Establishing the Dose of the Oral NK1 Antagonist | May 1, 2025 | EXHIBIT | PETITIONER |
S.P. Chawla et al., Establishing the Dose of the Oral NK1 Antagonist | May 1, 2025 | EXHIBIT | PETITIONER |
A. De Leon, Palonosetron (Aloxi): a second-generation 5-HT3 | May 1, 2025 | EXHIBIT | PETITIONER |
R.A. Duffy, Potential therapeutic targets for neurokinin-1 receptor | May 1, 2025 | EXHIBIT | PETITIONER |
Press Release, Eisai Co., FDA Approves ALOXIⓇ (Palonosetron HCl) | May 1, 2025 | EXHIBIT | PETITIONER |
Merck & Co., EMEND, package insert (2008) | May 1, 2025 | EXHIBIT | PETITIONER |
DailyMed, EMEND (aprepitant) Capsule | May 1, 2025 | EXHIBIT | PETITIONER |
U.S. Food and Drug Administration, General Considerations for the Clinical | May 1, 2025 | EXHIBIT | PETITIONER |
U.S. Food and Drug Administration, Q3A Impurities in New Drug Substances | May 1, 2025 | EXHIBIT | PETITIONER |
D.G. Warr et al., Efficacy and tolerability of aprepitant | May 1, 2025 | EXHIBIT | PETITIONER |
S.M. Grunberg et al., Effectiveness of a single-day three-drug regimen | May 1, 2025 | EXHIBIT | PETITIONER |
Press Release, GSK provides update on regulatory filings for Zunrisa | May 1, 2025 | EXHIBIT | PETITIONER |
P.J. Hesketh et al., The Oral Neurokinin-1 Antagonist Aprepitant | May 1, 2025 | EXHIBIT | PETITIONER |
G.S. Paulekuhn et al., Trends in active pharmaceutical ingredient salt | May 1, 2025 | EXHIBIT | PETITIONER |
S. Poli-Bigelli et al., Addition of the neurokinin 1 receptor antagonist | May 1, 2025 | EXHIBIT | PETITIONER |
T. Qiu et al., Antiemetic regimen with aprepitant in the prevention | May 1, 2025 | EXHIBIT | PETITIONER |
C. Rojas, The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits | May 1, 2025 | EXHIBIT | PETITIONER |
C. Ruhlmann & J. Herrstedt, Casopitant: a novel NK1-receptor antagonist | May 1, 2025 | EXHIBIT | PETITIONER |
R. Saito et al., Roles of substance P and NK1 receptor in the brainstem | May 1, 2025 | EXHIBIT | PETITIONER |
Ronald D. Schoenwald, Pharmacokinetics in Drug Discovery and Development | May 1, 2025 | EXHIBIT | PETITIONER |
A.G. Thomas, Netupitant and palonosetron trigger NK1 receptor | May 1, 2025 | EXHIBIT | PETITIONER |
K.E. Thummel, Gut instincts: CYP3A4 and intestinal drug metabolism, 117(11) | May 1, 2025 | EXHIBIT | PETITIONER |
D.S. Wang, Effect of aprepitant for the prevention of chemotherapy-induced | May 1, 2025 | EXHIBIT | PETITIONER |
W. Yeo et al., A randomized study of aprepitant, ondansetron | May 1, 2025 | EXHIBIT | PETITIONER |
S.F. Zhou, Drugs Behave as Substrates, Inhibitors and Inducers of Human | May 1, 2025 | EXHIBIT | PETITIONER |
Parenteral, Merriam-Webster | May 1, 2025 | EXHIBIT | PETITIONER |
NK1 receptor antagonist by Roche, Advances in Drug Discovery | May 1, 2025 | EXHIBIT | PETITIONER |
RxList, ALOXI (palonosetron HCl) Capsules | May 1, 2025 | EXHIBIT | PETITIONER |
DailyMed excerpts relating to ALOXI (palonosetron HCl) Capsules | May 1, 2025 | EXHIBIT | PETITIONER |
DailyMed excerpts relating to Aloxi (palonosetron HCl) Capsules | May 1, 2025 | EXHIBIT | PETITIONER |
PCT Publication WO 2011/061622, filed 18 November 2010 | May 1, 2025 | EXHIBIT | PETITIONER |
Provisional Patent Appl. 61/382,709, filed 14 September 2010 | May 1, 2025 | EXHIBIT | PETITIONER |
Provisional Patent Appl. 61/262,470, filed 18 November 2009 | May 1, 2025 | EXHIBIT | PETITIONER |
Drugs@FDA: FDA-Approved Drugs | May 1, 2025 | EXHIBIT | PETITIONER |
P. Li & L. Zhao, Developing Early Formulations: Practice and Perspective | May 1, 2025 | EXHIBIT | PETITIONER |
G. Sanso, Double capsule for the administration of active principles | May 1, 2025 | EXHIBIT | PETITIONER |
B. Cromie, Drug Combinations, 1(2) Current Medical Research and Opinion | May 1, 2025 | EXHIBIT | PETITIONER |
Notice: Power of Attorney | May 1, 2025 | PAPER | PETITIONER |
Expert Declaration of Dr. Stephen J. Peroutka | May 1, 2025 | EXHIBIT | PETITIONER |
Petition: as filed | May 1, 2025 | PAPER | PETITIONER |